Loading...
•
Sep 30, 2020
Ocugen Q3 2020 Earnings Report
Ocugen reported a net loss for the third quarter of 2020, with progress made in developing gene therapy and biologic product candidates.
Key Takeaways
Ocugen reported third quarter 2020 financial results with a net loss of $10.5 million, or $0.07 per share. The company's cash, cash equivalents, and restricted cash totaled $19.3 million as of September 30, 2020. Ocugen is on track to initiate four Phase 1/2a trials during 2021 and 2022.
Made steady progress towards starting OCU400 clinical trials in 2021.
Entered into a manufacturing contract for OCU200 with Kemwell Biopharma.
Fully repaid unsecured notes.
Raised capital of $10.1 million net proceeds in the third quarter, increasing its cash runway into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...